Related Experiment Video
Updated: Nov 28, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Neoadjuvant Therapy with Drug Arglabin for Breast Cancer with Expression of H-Ras Oncoproteins
Sergazy Adekenov1, Ainur Zhumakayeva1,2, Vladimir Perminov3
1JSC "International Research and Production Holding "Phytochemistry", Karaganda, Republic of Kazakhstan.
Backgrounds:
In breast cancer, blocking of Ras signaling and inhibition of H-Ras is quite promising. H-Ras may become a target for farnesyl transferase inhibitors, and in combination with other immunohistochemical factors it will contribute to the progression of a breast tumor.
Purpose:
The aim of this study was to evaluate the effectiveness of neoadjuvant therapy for breast cancer with the inclusion of farnesyl transferase inhibitor, arglabin interfering with the expression and concentration of H-Ras oncoproteins.
Methods:
Depending on the presence of H-Ras oncoproteins after Western-blot hybridization, the patients were divided a negative and positive expression of H-Ras groups.
Results:
Correlation analysis of methods used for determining the expression ability and concentration of H-Ras oncoproteins (immunohistochemistry and Western-blot analysis) demonstrated substantial statistical relationship Rs=0.71, p=0.03. The H-Ras oncoproteins were absent in patients receiving either "Arglabin" or standard AC regimen. However, in the AC + Arglabin group, there was a varying degrees of positive concentration of H-Ras oncoproteins (Kruskal-Wallis=6.92; p=0.03).
Conclusion:
These results indicate that Arglabin attenuates H-Ras oncoproteins expression which is a promising therapeutic target for breast cancer.
Insights
Farnesyl transferase inhibitor Arglabin shows promise in breast cancer treatment by reducing H-Ras oncoproteins. This targeted therapy may offer a new approach for managing breast tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Ras signaling blockade is a promising strategy in breast cancer therapy.
- H-Ras oncoproteins are implicated in breast tumor progression and can be targeted by farnesyl transferase inhibitors.
Purpose of the Study:
- To evaluate the efficacy of neoadjuvant therapy for breast cancer using the farnesyl transferase inhibitor Arglabin.
- To assess Arglabin's impact on the expression and concentration of H-Ras oncoproteins.
Main Methods:
- Patients were categorized into H-Ras negative and positive expression groups based on Western-blot analysis.
- Correlation between immunohistochemistry and Western-blot analysis for H-Ras oncoprotein detection was assessed.
Main Results:
- A significant statistical relationship (Rs=0.71, p=0.03) was found between immunohistochemistry and Western-blot analysis for H-Ras.
- H-Ras oncoproteins were absent in patients treated with Arglabin or standard AC regimen alone.
- The combination of AC plus Arglabin resulted in varying degrees of positive H-Ras oncoprotein expression (Kruskal-Wallis=6.92; p=0.03).
Conclusions:
- Arglabin demonstrates an ability to attenuate the expression of H-Ras oncoproteins.
- Reduced H-Ras oncoprotein expression suggests Arglabin is a potential therapeutic target for breast cancer.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...